Bonus/Dividend/Fundraising: Pharma Stock To Consider 3 Corporate Actions On 2nd August

A pharmaceutical firm in India with WHO-GMP certification is JFL Life Sciences Pvt. Ltd. It produces an extensive range of pharmaceutical formulations. JFL is well-known in international markets, having exported to over ten established and developing nations worldwide. Its main activities are product manufacturing and marketing in various markets.

JFL Life Sciences has informed the stock exchanges about the Board Meeting to be held on 02-Aug-2024 to consider and approve an increase in authorised capital/bonus shares/fundraising/dividend.

Following the news, the shares of JFL Life Sciences ended at a 5% upper circuit limit at Rs 55.65 apiece on NSE on Friday with a market cap of Rs 61.21 Cr.

On 15th July, the company informed stock exchanges that it had paid-up equity share capital not exceeding Rs.10 Crore and net worth not exceeding Rs. 25 Crore in FY24.

Earlier this month on 04-07-2024, the company received an order from PHIL CAPITAL TRADING SOLUTIONS INC, MANILA 1740 PHILIPPINES to supply in parts in a year at Manila Port, Phillippines for a total cash consideration of 1662000 $ (Approx. Rs. 138.76 Million). The order will be executed in 1 year.

In order to support the Make in India initiative, JFL Life Sciences Limited has declared that, as of 07-07-2024, it has released 16 new products in the categories of tablets, capsules, gel, syrup, and injections. A wide variety of products are available from JFL Life Sciences Limited, such as the J Cold Gold tablet, J-Reb DSR capsule, J-Finance P tablet, J-Diclo P tablet, and J-Cyclo P tablet.capsule J-Omepra, etc.

JFL Life Sciences Limited reported a net revenue of Rs 47.07 Cr in FY24 compared to Rs 44.47 Cr in FY23 while its total expenses reached Rs 43.27 Cr in FY24 which was Rs 40.75 Cr in FY23. The company reported a net profit of Rs 3.31 Cr in FY24 against Rs 2.81 Cr in FY23.

The pharma stock reached a 52-week-high of Rs 63.85 on (08-Jul-2024) and a 52-week-low of Rs 36.05 on (14-Mar-2024) indicating that at the current market price level, the stock has gained 54.37% from 52W Low.
During the March 2024 quarter the company reported promoter shareholding of 67.47% and public stake of 32.53%.